Revolutionary Tumor RNA Testing Paves the Way for Innovative New Drug Treatments
A Personal Journey Through Stage IV Pancreatic Cancer: Adam Deal’s Story
In an unexpected twist of fate, Adam Deal’s active pursuit of fitness led him to confront a life-altering diagnosis. What began as a quest to look good for a friend’s wedding quickly spiraled into a battle with stage IV pancreatic cancer. Adam’s journey highlights the importance of awareness, genetic testing, and innovative treatments that can change lives.
The Start of an Unforeseen Challenge
In the summer of 2017, Adam decided to shed some pounds in preparation for his friend’s wedding. To his delight, he achieved a toned physique, showcasing a six-pack for the first time in years. However, on the wedding day in September, he noticed the tuxedo that once fit perfectly was now too loose. His wife’s concern prompted him to consult with his primary care doctor upon returning home to Cleveland.
- Signs of Concern: Adam experienced unexplained weight loss and heartburn.
- Initial Diagnosis: An ultrasound revealed lesions on his liver, leading to further tests.
Stunning News: A Life-Changing Diagnosis
On his 33rd birthday, Adam received the shocking news that he had stage IV pancreatic cancer. The revelation came as he stood in his parents’ kitchen, where his father delivered the devastating news. Thoughts raced through Adam’s mind about his young children and the weight of the diagnosis. Just ten days after his diagnosis, he began chemotherapy, facing the grim prognosis of having only two to twelve months to live.
Examining the Symptoms
Reflecting on his symptoms, Adam realized he had been experiencing fatigue and soreness, which he attributed to his demanding workout routine. The only significant warning sign was the dramatic 40-pound weight loss over three months. Like many others, Adam believed that fatigue was merely a byproduct of his busy life.
Innovative Treatment Through Genetic Testing
After starting chemotherapy with FOLFIRINOX at the Cleveland Clinic, Adam encountered significant side effects. Despite the initial treatment, the tumors did not respond as hoped. During this time, he pursued genetic testing for his tumors but found no actionable mutations.
- A New Hope: Dr. Aaron Viny, a cancer researcher and family friend, suggested exploring alternative options.
- Breakthrough Discovery: Further testing at Memorial Sloan Kettering Cancer Center (MSKCC) revealed a rare gene fusion, NRG1, which is more common in lung and breast cancers.
In February 2019, Adam began participating in a clinical trial for a new drug, MCLA-128, aimed at targeting the NRG1 fusion. Though it was a risky decision due to the lack of prior data on its efficacy for pancreatic cancer, Adam and his team were hopeful.
Remarkable Results and Ongoing Trials
After starting the trial in March 2019, Adam experienced a significant improvement in his condition. His CA 19-9 levels, a crucial marker for pancreatic cancer, dropped from 422 to 11. He began to regain weight and enjoy life again, all while avoiding the harsh side effects of traditional chemotherapy.
- Current Status: After seven months of treatment, while his CA 19-9 level rose slightly to 51, scans showed that his tumors remained stable and inactive.
- Expanding Opportunities: Due to Adam’s success, MSKCC launched a clinical trial for others with the NRG1 fusion, aiming to provide new hope for pancreatic cancer patients.
A Legacy of Hope and Awareness
Adam’s journey serves as a beacon of hope for those battling similar challenges. He advocates for comprehensive genomic testing and encourages others to explore all available treatment options beyond traditional chemotherapy. His story emphasizes the critical role of research and innovation in the fight against cancer.
In a heartfelt note, it’s important to remember that Adam bravely faced his diagnosis and contributed to the advancement of treatments that may help countless others. His legacy continues to inspire, reminding us that hope and determination are powerful allies in the fight against cancer.
